Cigna news is the latest iceberg hit by Obamacare

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt
Cigna news is the latest iceberg hit by Obamacare

Obamacare's defenders must feel like the band that played as the Titanic sank into the icy waves of the North Atlantic. Because if Obamacare wasn't a sinking ship already, it certainly is now.

One of the nation's largest health insurers, Cigna Corp., announced Thursday, "it would not expand its individual Obamacare plans into more states next year," according to Reuters. The Cigna announcement marks the latest blow the already-cracked windshield that is Obamacare.

When the Patient Protection and Affordable Care Act (Obamacare) was crafted in 2009/2010, the nation's largest health insurers, pharmaceutical companies, and health providers were allowed to collude with the White House and Congressional Democrats.

President Obama said that the resulting legislation "...would end the worst practices of insurance companies… No longer would they be able to arbitrarily and massively raise premiums like Anthem Blue Cross recently tried to do in California — up to 39 percent increases in one year in the individual market… And my proposal says that if you still can't afford the insurance in this new marketplace, even though it's going to provide better deals for people than they can get right now in the individual marketplace, then we'll offer you tax credits to do so — tax credits that add up to the largest middle-class tax cut for health care in history. After all, the wealthiest among us can already buy the best insurance there is, and the least well off are able to get coverage through Medicaid."

Obamacare has done none of this. Reuters notes: "Insurers including Aetna Inc (AET.N), UnitedHealth Group Inc (UNH.N) and Anthem Inc (ANTM.N) - which has agreed to buy Cigna - say they are losing money on the exchanges because of lower-than-anticipated enrollments. Enrollees are also sicker and older than expected."

Cigna continues to take a loss from their individual plans under Obamacare.

Couple that with the complete collapse of some state exchange programs, such as those in Oregon, Maryland, Massachusetts, and Nevada, and what we are seeing is a not a system under a tremendous amount of strain, but a catastrophic failure in progress. The four aforementioned states lost $474 million in the collapse of their state Obamacare exchanges. And we haven't even touched upon the premium rate hikes for 2017, many of which make Obama's complaints about 39 percent rate hikes seem quaint.

In Tennessee, Cigna and Humana requested rate hikes of 46-percent and 44.3-percent, respectively.
Charles Gaba at ACASighnups.net has run numbers for 49 of the 50 states (excluding Louisiana) and estimates the aggregate 2017 premium rate hike to be 25.1 percent. That's less than what Anthem asked for in California during the original Obamacare debate, but it's still significant and well outside where the CBO projected we'd be today.

The failure of four state exchanges in 2014 should have been the iceberg that sunk this government program, yet the ship has limped. on

Now with premium rate hikes causing rancor among the insured and Cigna and other big insurers either abandoning ship or reducing their exposure on state exchanges, one would think that Obamacare has hit enough icebergs for the politicians to stop re-arranging the deck chairs and make plans to repeal the disastrous law.

http://www.washingtonexaminer.com/cigna-news-...le/2606508
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 1

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 99

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Analyzing RTX: Trends in Short Interest and Market Sentiment

Updated Category News Views 176

Understanding RTX's Recent Market Movements RTX Corp has seen a notable shift in its market dynamics recently. The company's short interest, defined as the number of shares sold short but not yet covered, has decreased by 7.63% since the last reporting period. Currently, there are approximately 16.18 million shares sold short, equating to 1.21% of all shares available for...

Continue Reading
Celebrate Christmas Spirit with Personalized PrayerSongs

Updated Category News Views 156

Celebrate the Joy of Christmas with PrayerSong Bring Love Into Your Home with a PrayerSong for Your Family and Friends When the holiday season arrives, the focus shifts beyond material gifts. Instead, it’s about nurturing connections filled with love, faith, and meaningful moments. This Christmas, PrayerSong provides families with a unique opportunity to honor loved...

Continue Reading
Understanding the Short Selling Landscape of Analog Devices

Updated Category News Views 153

Analyzing Short Interest for Analog Devices As investors navigate the ever-changing stock market, understanding short interest can provide valuable insights into market sentiment regarding Analog Devices (NYSE: ADI). Recently, it was reported that Analog Devices has seen a notable increase of 4.11% in its short percent of float. Currently, there are approximately 7.52...

Continue Reading
Future of Clinical Trials: Exploring Market Growth to USD 85.37 Billion

Updated Category News Views 71

Understanding Clinical Trials and Their Importance Clinical trials serve as a fundamental pillar in advancing medical knowledge and enhancing patient care. These trials encompass a detailed and thorough process involving participant recruitment, intervention administration, data collection, and result analysis. The outcomes produced from clinical trials play a crucial...

Continue Reading